A long-acting drug injected every two months is more efficient at avoiding HIV than the pills most commonly used by people at threat of getting the infection, according to research launched Tuesday at an international HELP conference.
The drug cabotegravir was evaluated on more than 4,500 cisgender males who have sex with guys and transgender ladies who have sex with men in 43 nations. While Truvada, the pill utilized usually to obstruct the virus, is likewise highly effective, the injectable drug showed to be even much better, the research reveals.
Possibly more important, an injection every 2 months might allow more individuals to remain on medication, called “pre-exposure prophylaxis” or PREPARATION, that obstructs the infection. Individuals whose healthcare is inconsistent, consisting of homeless individuals, intravenous drug users and others in unsteady circumstances, have difficulty staying on the everyday tablets. Others hesitate to get them because of the stigma still associated with HIV.
” Offering people an option of an injection every eight weeks instead of taking a day-to-day tablet to prevent HIV offers options and flexibility,” Monica Gandhi, San Francisco co-chair of the HELP 2020 conference, said in an email. The wo